Department of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.
Department of Internal Medicine B, University Clinic Münster, 48149 Münster, Germany.
Cells. 2024 Oct 16;13(20):1707. doi: 10.3390/cells13201707.
Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.
代谢相关脂肪性肝炎(MASH)是肝硬化的一个主要原因。MASH 相关性肝硬化可导致肝脏并发症,目前尚无特异性治疗方法。为了开发新的治疗方法,需要动物模型。本研究旨在建立一种快速的大鼠 MASH 相关性肝硬化动物模型,以反映人类疾病。采用四氯化碳(CCl)注射联合高脂肪西方饮食(WD)诱导 MASH 相关性肝硬化。为了加速肝脏损伤,动物饮用添加苯巴比妥(PB)的水,采用两种不同方案。大鼠发展为晚期 MASH 相关性肝硬化,表现为门静脉高压、血液生化、肝气球样变、脂肪变性、炎症和纤维化。重要的是,长期给予低剂量 PB(LT)的大鼠在 6 周后出现腹水,而短期给予高剂量 PB(ST)的大鼠在 8 周后出现腹水。ST 和 LT 治疗组大鼠的门静脉压(PP)升高,平均动脉压(MAP)降低。值得注意的是,只有 LT 组观察到肝细胞气球样变。CCl 中毒和 WD 联合 LT 低剂量 PB 给药可建立快速且可重复的大鼠模型,模拟人类失代偿性 MASH 相关性肝硬化。因此,CCl + WD 联合 LT 低剂量苯巴比妥治疗可能是 MASH 相关性肝硬化药物开发的首选大鼠动物模型。